Skip to main content


We rely on the generosity and financial support from the community to advance scientific research so more RET-positive lung cancer patients can live fuller, healthier lives. We are committed to financial accountability and transparency, and we aim to be the best possible stewards of the generous financial contributions from our donors and partners.

Since our inception in 2021, we have awarded more than $1 million in RET-positive cancer research grants. We also educate patients and caregivers across the country about how participating in clinical trials and biomarker testing can improve RET-positive treatment options and patient survival.

2022 Operating Revenue

$872,265 General Contributions
$50,000 Grants

$922,265 Total 

2022 Functional Expenses

$300,956 Program
$747 Fundraising
$0 Management & General

$301,703 Total

2022 Form 990

View 990

2021 Operating Revenue

$216,750 General Contributions

$216,750 total

2021 Functional Expenses

$109,364 Program
$0 Fundraising
$0 Management & General

$109,364 Total

2021 Form 990

View 990

We are a registered 501(c)(3) nonprofit organization (EIN # 87-0957020). Our fiscal year is January through December. If you have any questions about donations, grants, and upcoming projects, please contact us at

Candid gold seal 2024